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subjects with a50% reduction in bleeding events, the incremental cost-effective-
ness ratio in the prophylaxis vs. on demand period was US$ 77,067 per bleeding
event avoided. CONCLUSIONS: Cost-effectiveness ratios are within the commonly
accepted willingness-to-pay threshold. The incremental cost-effectiveness ratio
noticeably was more favorable in responders, which is totally attributable to the
marked difference in effectiveness. Moreover the Incremental cost per bleed
avoided during prophylactic period suggest prophylaxis to be more cost effective in
children, who could derive the greatest benefit in terms of joint disease and long-
term disability.
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OBJECTIVES: Invasive fungal infections (IFIs) have emerged as the major infection-
related cause of morbidity and mortality in patients undergoing hematopoietic
stem cell transplantations (HSCT). Ullmann et al published a RCT in allogeneic
HSCT recipients with grade 2–4 or extensive chronic GVHD that compared the
efficacy of posaconazole and fluconazole in the prevention of IFIs. Posaconazole
was shown to be as effective as fluconazole in preventing IFIs (5.3% vs. 9.0%) and
reduced IFI-related mortality (2.7% vs. 8.0%). We evaluated posaconazole cost-ef-
fectiveness from the Turkish health care system perspective. METHODS: A trial-
based decision-tree model was developed. The probabilities of experiencing an IFI,
IFI-related death, and death from other causes over 112 days post treatment were
provided from Ullmann trial. The model was extended to a lifetime horizon, in
which survival within the initial two years was based on the Ullmann trial and
survival beyond two years was based on adjustment of national life tables by stan-
dardize mortality rates obtained from literature. IFI-related costs were provided
from local literature. The model was used to estimate costs, life-years saved (LYS),
and the incremental cost-effectiveness ratio (ICER) of posaconazole vs. fluconazole
(year 2012). RESULTS: Posaconazole treatment appeared to be more effective with
increased LYS (3.90 vs. 3.67) however, more costly (32,717 USD vs. 31,298 USD) than
the alternative over a lifetime horizon. The ICER of posaconazole was 6,373 USD/
LYS compared to fluconazole. Univariate sensitivity analysis was conducted to
assess the effects of parameter uncertainty, particularly concerning treatment ef-
ficacy and long-term mortality. With almost all assumptions that were analyzed,
posaconazole ICER was well below the national gross domestic product per capita
per LYS threshold (10,444 USD/LYS). CONCLUSIONS: Posaconazole appeared to be
cost-effective vs. fluconazole in the prophylaxis of IFIs among patients with GVHD
undergoing allogeneic HSCT.
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OBJECTIVES: To assess the costs and outcomes of parecoxib used in combination
with opioids vs. opioids alone in the post-operative management of surgical pa-
tients in Greece. METHODS: A model comparing parecoxib plus opioid treatment,
to opioids alone during the first three days post-surgery was developed. Clinical
efficacy was based on a phase-III randomized, double-blind clinical trial that also
provided the frequencies of occurrence of clinically meaningful opioid-related ad-
verse events (CMEs) for both treatment arms. Resource use associated with each
CME was elicited via strictly structured questionnaire based interviews to a panel
of experts (surgeons and anesthesiologists). Cost calculations followed a third
party payer perspective (Euros, 2012). Treatment effectiveness was calculated in
Summed Pain Intensity scores (SPI). RESULTS: According to the clinical trial, pa-
tients under parecoxib plus opioids had lower pain scores (SPI 59.20 vs. 80.80) and
fewer CMEs (0.62 vs. 1.04 per patient) compared to opioids alone, for a 3-day period.
This led to a full offset of the excess cost of the addition of parecoxib and to
potential savings of 858€ (total cost per patient: 819.08 vs. 1,677.08, respectively).
Savings were mainly attributable to decreased CMEs, reductions in ICU and general
ward bed-days as well as to reduced physician and nurse time. Results were sen-
sitive with regards to probabilities of occurrence or co-occurrence of CMEs (2
CMEs occurring simultaneously), although the above was of limited impact. Med-
ication costs had a minimal impact on the results of the sensitivity analysis. Ex-
tending the model cycle to 5-days post-operatively was associated with additional
savings of 1,139.9€ per patient, compared to opioid use alone (total cost per patient:
1,063.2 vs. 2,203.1 respectively). CONCLUSIONS: Parecoxib can be a valuable addi-
tion to opioid treatment for post operative pain, improving pain relief, reducing the
probabilities of CME occurrence and lowering overall costs of treatment.
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OBJECTIVES: Pharmacoeconomic aspects of application of dexketoprofen trometa-
mol in routine clinical practice in Russia remain unclear. The aim of our research is
comparative pharmacoeconomic analysis of administration of dexketoprofen tro-
metamol in reduction of acute post-traumatic pain. METHODS: The estimation of
pain relief strategies with dexketoprofen and diclofenac was performed by a cost-
effectiveness analysis based on modeling method. We have calculated the costs of
treatment for pain syndrome in injuries of lower extremities in two groups of 100
patients, who received dexketoprofen or diclofenac. The choice of diclofenac was
motivated by the fact that it is the most frequently prescribed NSAID included into
the National Essential Drug List. The main efficiency measure was the level of
analgesia achieved within one hour after administration of a medication estimated
using Visual Analog Scale (VAS). Only direct costs of pain syndrome relief were
included in cost analysis in our model. RESULTS: The costs of therapy in diclofenac
and dexketoprofen groups were 1033.0 RUB and 1611.1 RUB, respectively. Final
cost-efficiency ratio was 39.73 RUB per unit in diclofenac, and 20.92 in dexketopro-
fen group. Incremental cost-effectiveness ratio (11.34 RUB/unit) revealed that treat-
ment with dexketoprofen trometamol demands additional funding for signifi-
cantly greater effect compared to diclofenac. Sensitivity analyses indicated these
results to be robust. CONCLUSIONS: The results of our study suggest that the
application of dexketoprofen trometamol has the best cost-effectivness in acute
posttraumatic syndrome compared to traditionally prescribed diclofenac.
PSY24
ECONOMIC EVALUATION OF OPIOID SUBSTITUTION TREATMENT (OST) IN
GREECE
Geitona M1, Carayanni V2, Petratos P1, Androutsou L1
1University of Peloponnese, Korinth, Greece, Greece, 2Technological Educational Institute of
Athens, Athens, Greece, Greece
OBJECTIVES: To perform an economic evaluation of OST in Greece. Individuals
wishing to participate in OST are increasing, since only 4,046 opioid-dependent
persons were participating in OST programs in 2008, whilst 5,386 who were willing
to receive OST were on the waiting list for treatment, with a mean waiting-list time
of 6 years.METHODS:Data were gathered from theK and EKTEPN, the Greek
REITOX (European Information Network on Drugs and Drug Addiction) Focal Point
of the European Monitoring Centre for Drugs and Drug Addiction .The total number
of patients included in the analysis was 4046 . Statistical tests were used to test the
homogeneity between treatment programs as well as among geographical areas.
Cost-minimization and cost-effectiveness analyses were conducted to compare
methadone and buprenorphine monotherapy with buprenorphine–naloxone. A
budget-impact analysis was undertaken in order to estimate the potential costs
and savings that could be gained from the expansion of OST programs in Greece.
Deterministic and probabilistic sensitivity analyses were performed. To represent
the output uncertainty from probabilistic sensitivity analysis scatterplots of 2000
simulated ICERs were produced on the cost-effectiveness plane as well as cost-
effectiveness acceptability curves. RESULTS: Cost-minimization analysis pre-
dicted that buprenorphine monotherapy is more costly than buprenorphine–nal-
oxone. Cost-effectiveness analyses demonstrated that buprenorphine–naloxone
was the dominating therapy in terms of mortality avoidance and completion of
treatment. In comparison to methadone, buprenorphine–naloxone reduced the
mean cost by 49%; increased by 1.5-fold the percentage of participants complet-
ing their treatment; and reduced by2.5-fold the percentage of deaths. Sensitivity
analyses did not reverse the findings. CONCLUSIONS: Our findings demonstrated
that switching to buprenorphine-naloxone treatment would result in significant
savings, reduce waiting lists and increase access to OST. The introduction of phar-
macoeconomic studies in Greece would support rational decision-making in an era
of economic recession and uncertainty.
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OBJECTIVES: Early diagnosis and aggressive treatment is crucial in rheumatoid
arthritis to prevent disease development, joint destruction and cardiovascular dis-
ease, which start within first 2 years of disease. This study aims to perform cost-
effectiveness analysis of etanercept in early rheumatoid arthritis (ERA) treatment,
defined as disease duration from 3 months to 2 years, from the public payer per-
spective in Brazil. METHODS: A decision model was developed to simulate ERA
evolution after treatment with etanercept(50mg/week)methotrexate (ETNMTX)
or methotrexate (MTX) as first-line therapies and their associated direct costs over
a 5-year time horizon. An initial decision tree estimated the number of patients
entering Markov model in the following health states: ‘remission’, ‘non-remission’,
‘discontinuation’, and ‘non-response’ (ACR20 criteria). Patients starting on ‘remis-
sion’ or ‘non-remission’ states could transit between them or to ‘orthopedic inter-
vention’ (ORT), ‘cardiovascular event – myocardial infarction/stroke’ (CVE), ‘all-
cause death’, ‘cardiovascular death’, and ‘surgery-related death,’ or switch to
second-line (adalimumabMTX or infliximabMTX). Patients initiating on ‘dis-
continuation’ or ‘non-response’ states switched directly to second-line therapy.
Remission (DAS282.6) was considered as effectiveness outcome. Clinical data
were extracted from literature, and costs from Brazilian official databases, pre-
sented in 2012 USD. Univariate sensitivity analyses were performed. A 5% discount
rate was applied annually for costs and benefits. RESULTS: For each 1,000 patients,
244 and 106 were in remission at year 5 for ETNMTX and MTX groups, respec-
tively. The number of [ORT; CVE] was [102; 38] for ETNMTX and [125; 43] for MTX.
Projected treatment costs for ETNMTX and MTX were 54,433,960USD, and
40,175,096USD, respectively. In cost-effectiveness analysis, ETNMTX was the
most effective alternative (incremental effectiveness: 138) and presented an incre-
mental cost (14,258,866USD) with incremental cost-effectiveness ratio of
102,968USD per remission achieved. CONCLUSIONS: Etanercept in ERA treatment
showed to prevent disease progression, with more achieved remissions and
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